U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H18N4OS
Molecular Weight 386.47
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of AXITINIB

SMILES

CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(\C=C\C4=CC=CC=N4)=NN3

InChI

InChIKey=RITAVMQDGBJQJZ-FMIVXFBMSA-N
InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+

HIDE SMILES / InChI
Molecular Formula C22H18N4OS
Molecular Weight 386.47
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:19:06 UTC 2023
Edited
by admin
on Fri Dec 15 16:19:06 UTC 2023
Record UNII
C9LVQ0YUXG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AXITINIB
DASH   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)-BENZAMIDE
Systematic Name English
AXITINIB [VANDF]
Common Name English
AG-013736
Code English
AXITINIB [ORANGE BOOK]
Common Name English
AXITINIB [MI]
Common Name English
Axitinib [WHO-DD]
Common Name English
axitinib [INN]
Common Name English
NSC-757441
Code English
AG-13736
Code English
AXITINIB [MART.]
Common Name English
BENZAMIDE, N-METHYL-2-((3-((1E)-2-(2-PYRIDINYL)ETHENYL)-1H-INDAZOL-6-YL)THIO)-
Systematic Name English
AXITINIB [JAN]
Common Name English
INLYTA
Brand Name English
N-METHYL-2((3-((1E0-2-(PYRIDIN-2-YL)ETHENYL)-1H-INAZOL-6-YLSUFANYL)BENZAMIDE
Common Name English
AXITINIB [USAN]
Common Name English
Classification Tree Code System Code
WHO-ATC L01XE17
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
NCI_THESAURUS C1742
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
EMA ASSESSMENT REPORTS INLYTA (AUTHORIZED: CARCINOMA, CANCER CELL)
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
FDA ORPHAN DRUG 730120
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
WHO-VATC QL01XE17
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
NCI_THESAURUS C93259
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
NDF-RT N0000175605
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
NCI_THESAURUS C129825
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
FDA ORPHAN DRUG 230706
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
EU-Orphan Drug EU/3/10/844
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
LIVERTOX NBK548139
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
FDA ORPHAN DRUG 240607
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
Code System Code Type Description
DRUG CENTRAL
4225
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
WIKIPEDIA
Axitinib
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
PRIMARY
RXCUI
1242999
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID3049049
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
MESH
C503983
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
PRIMARY
LACTMED
Axitinib
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
PUBCHEM
6450551
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
PRIMARY
MERCK INDEX
m2153
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY Merck Index
FDA UNII
C9LVQ0YUXG
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
SMS_ID
100000089442
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
PRIMARY
EVMPD
SUB25427
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
ChEMBL
CHEMBL1289926
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
NDF-RT
N0000020000
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
PRIMARY Receptor Tyrosine Kinase Inhibitors [MoA]
NSC
757441
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
PRIMARY
IUPHAR
5659
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
USAN
RR-15
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
PRIMARY
INN
8720
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
DRUG BANK
DB06626
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
DAILYMED
C9LVQ0YUXG
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
CHEBI
66910
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
NCI_THESAURUS
C38718
Created by admin on Fri Dec 15 16:19:07 UTC 2023 , Edited by admin on Fri Dec 15 16:19:07 UTC 2023
PRIMARY
CAS
319460-85-0
Created by admin on Fri Dec 15 16:19:06 UTC 2023 , Edited by admin on Fri Dec 15 16:19:06 UTC 2023
PRIMARY
Related Record Type Details
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2
TARGET -> INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1
TARGET -> INHIBITOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BCR-ABL KINASE T315I MUTANT (IMATINIB RESISTANT)
TARGET -> INHIBITOR
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
MAJOR
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3
TARGET -> INHIBITOR
Related Record Type Details
Structure of N-METHYL-2-((3-(3-(2-PYRIDYL)OXIRAN-2-YL)-1H-INDAZOL-6-YL)SULFANYL)BENZAMIDE
METABOLITE -> PARENT
Structure of N-METHYL-2-((3-((E)-2-(1-OXIDOPYRIDIN-1-IUM-2-YL)VINYL)-1H-INDAZOL-6-YL)SULFANYL)BENZAMIDE
METABOLITE -> PARENT
Structure of SULFONYL AXITINIB
METABOLITE -> PARENT
Structure of AXITINIB SULFOXIDE PYRIDINE-N-OXIDE
METABOLITE -> PARENT
Structure of N-DEMETHYL-N-(HYDROXYMETHYL)AXITINIB
METABOLITE -> PARENT
Structure of AXITINIB SULFOXIDE
METABOLITE -> PARENT
URINE
Structure of PF-04621675
METABOLITE INACTIVE -> PARENT
MAJOR
PLASMA
Related Record Type Details
Structure of AXITINIB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966